NCT01310114View on ClinicalTrials.gov

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

PHASE2TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Stroke, AcuteMiddle Cerebral Artery StrokePosterior Cerebral Artery Stroke
Interventions
BIOLOGICAL

Human Placenta-Derived Cells PDA001- (cenplacel-L)

240 mL of intravenous infusion

DRUG

Placebo

Thawed placebo

Trial Locations (1)

37403

Chattanooga Center for Neurologic Research, Chattanooga

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Celularity Incorporated

INDUSTRY